Acute skin radiation toxicity seen with concurrent T-DM1: A single institutional report of 35 patients

Trastuzumab emtansine (T-DM1) is a novel therapeutic for HER2+ breast cancer patients with residual disease after neoadjuvant chemotherapy. Concurrent radiotherapy (RT) is offered to a subset of patients based on results from the KATHERINE trial which showed a favorable safety profile. With emerging...

Descripción completa

Detalles Bibliográficos
Autores principales: Dastgheyb, Sana Sara, Kim, Kristine, Doucette, Abigail, Freedman, Gary, Shah, Payal, Makhlin, Igor, Clark, Amy, Taunk, Neil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982262/
https://www.ncbi.nlm.nih.gov/pubmed/36566691
http://dx.doi.org/10.1016/j.breast.2022.12.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982262/
https://www.ncbi.nlm.nih.gov/pubmed/36566691
http://dx.doi.org/10.1016/j.breast.2022.12.002

Ejemplares similares